Study of Prognostic Factors in Patients with Colorectal Cancer and Central Nervous System Metastasis: A Retrospective Analysis

Article Sidebar

30-Nov-6102.pdf
Published Nov 29, 2024
DOI: https://doi.org/10.18103/mra.v12i11.6102

Downloads

Download data is not yet available.

Submit your own article

Register as an author to reserve your spot in the next issue of the Medical Research Archives.

Author Registration

Join the Society

The European Society of Medicine is more than a professional association. We are a community. Our members work in countries across the globe, yet are united by a common goal: to promote health and health equity, around the world.

Join Europe’s leading medical society and discover the many advantages of membership, including free article publication.

Membership

Main Article Content

Daniella DS Arruda
Instituto Brasileiro de Controle do Câncer, São Paulo, Brazil
Mauro DS Donadio
Centro Paulista de Oncologia - Oncoclinicas, São Paulo, Brazil
Maria Leticia G Silva
[email protected]
Celso AL Mello, (in memoriam)
AC Camargo Cancer Center, São Paulo, Brazil

Abstract

Background: Metastasis of colorectal cancer to the central nervous system (CNS) is relatively rare but leads to shorter survival for these patients, even with improvements in palliative treatments.


Objectives: The primary objective of this study was to assess the overall survival of patients with brain metastasis from colorectal cancer treated at the A.C. Camargo Cancer Center. The secondary objectives were to identify clinical and epidemiological factors, correlate clinicopathological factors with overall survival, and describe prognostic factors associated with CNS metastasis.


Methods: We retrospectively evaluated patients with metastatic colorectal cancer and CNS involvement treated from January 2002 to August 2020 at a single cancer center.


Results: We identified 46 patients with a median age of 63.9 years; 50% were male, and 80% had a good performance status. The predominant primary site was the left colon (71.7%). Sixty percent were stage IV, 71.7% had previously presented with lung metastasis, and 76.7% had a high volume of lung disease. RAS mutations were detected in 56.5% of the pts. Progression to the CNS occurred after a median of three treatment lines, with a median time of 49.5 months between diagnosis and progression to the CNS. Sixty percent had supratentorial lesions, and 55.6% had only one lesion. After a median follow-up time of 27.2 months, the overall survival was 6.4 months. Surgery and radiation were associated with improved overall survival (HR 0.24, 95% CI 0.09-0.67; p = 0.006; and HR 0.20, 95% CI 0.08-0.5; p = 0.001, respectively).


Conclusion: Our study found that most patients with CNS metastasis experienced progression after three lines of palliative treatment, had prior high-volume lung metastasis, and presented with left-sided tumors. Surgery and radiation may improve overall survival.

Keywords: colorectal cancer, CNS metastasis, palliative care

Article Details

How to Cite
ARRUDA, Daniella DS et al. Study of Prognostic Factors in Patients with Colorectal Cancer and Central Nervous System Metastasis: A Retrospective Analysis. Medical Research Archives, [S.l.], v. 12, n. 11, nov. 2024. ISSN 2375-1924. Available at: <https://esmed.org/MRA/mra/article/view/6102>. Date accessed: 12 dec. 2024. doi: https://doi.org/10.18103/mra.v12i11.6102.
ABNT APA BibTeX CBE EndNote - EndNote format (Macintosh & Windows) MLA ProCite - RIS format (Macintosh & Windows) RefWorks Reference Manager - RIS format (Windows only) Turabian
Issue
Vol 12 No 11 (2024): November Issue, Issue 11, VOl.12
Section
Research Articles

The Medical Research Archives grants authors the right to publish and reproduce the unrevised contribution in whole or in part at any time and in any form for any scholarly non-commercial purpose with the condition that all publications of the contribution include a full citation to the journal as published by the Medical Research Archives.

 

References

1. Ervik M, Lam F, Laversanne M, et al. Global Cancer Observatory: Cancer Over Time. Available online: https://gco.iarc.fr/overtime (accessed on 23 October 2024).
2. Ferlay J, Ervik M, Lam F, et al. Global Cancer Observatory: Cancer Today. Available online: https://gco.iarc.fr/today (accessed on 23 October 2024).
3. Ferlay J, Laversanne M, Ervik M, et al. Global Cancer Observatory: Cancer Tomorrow. Available online: https://gco.iarc.fr/tomorrow (accessed on 23 October 2024).
4. Estimativa 2020: incidência de câncer no Brasil / Instituto Nacional de Câncer José Alencar Gomes da Silva – Rio de Janeiro: INCA, 2019.
5. Christensen T, Spindler K, Palshof J, et al. Systematic review: brain metastases from colorectal cancer—Incidence and patient characteristics. BMC Cancer, 2016;1:16:260.
6. Grothey A, Sargent D, Goldberg R, Schmoll H-J. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J. Clin. Oncol. 2004;22:1209–14.
7. Zang Y, Gu X, Xiang J, et al. Brain Metastases from Colorectal Cancer: Microenvironment and Molecular Mechanisms. Int J Mol Sci. 2012;13(12):15784-800.
8. Ogino S, Shima K, Meyerhardt J, et al. Predictive and prognostic roles of BRAF mutation in stage III colon cancer: results from intergroup trial CALGB 89803. Clin Cancer Res. 2012;18:890-900.
9. Yaeger R, Cowell E, Chou J, et al. RAS mutations affect pattern of metastatic spread and increase propensity for brain metastasis in colorectal cancer. Cancer 2015;121:1195-203.
10. Qiu M, Hu J, Yang D, et al. Pattern of distant metástases in colorectal cancer: a SEER based study. Oncotarget 2015;6:38658-66.
11. Mongan J, Fadul C, Cole B, et al. Brain metastases from colorectal cancer: Risk factors, incidence, and the possible role of chemokines. Clin. Colorectal Cancer. 2009;8,100–5.
12. Gaspar L, Scott C, Rotman M, et al. Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials.Int J Radiat Oncol Biol Phys. 1997;37(4):745-51.
13. Fountzilas C, Chang K, Hernandez B, et al. Clinical characteristics and treatment outcomes of patients with colorectal cancer who develop brain metastasis: a single institution experience. J Gastrointest Oncol. 2017;8(1):55-63.
14. Cagney D, Martin A, Catalano P, et al. Incidence and prognosis of patients with brain metastases at diagnosis of systemic malignancy: a population-based study. Neuro Oncol. 2017;19(11):1511-21.
15. Nozawa H, Ishihara S, Kawai K, et al. Brain Metastasis from Colorectal Cancer: Predictors and Treatment Outcomes. Oncology. 2017;93(5):309-14.
16. Bonadio R, Freitas G, Batista D, et al. Epidemiology and Outcomes of Patients With Brain Metastases From Colorectal Cancer—Who Are These Patients? Clin Colorectal Cancer. 2021;20(3):e195-e200.
17. Teixeira B, Rider A, Holbrook T, et al. Overall cancer survival inequalities in the state of São Paulo: A comparison between public and private systems. JCO 40, 6525-6525(2022). doi: 10.1200/JCO.2022.40.16_suppl.6525
18. L. Bittencourt Hinrichsen1 ∙ M.T. Tsukazan2 ∙ A. Vigo, et al. P12.03 Public Versus Private Care Patients Treated in the Same Hospital. Are the Patients the Same? Journal of Thoracic Oncology, Volume 16, Issue 3, S325. doi: 10.1016/j.jtho.2021.01.499
19. Tin Tin S, Elwood JM, Lawrenson R, et al. Differences in Breast Cancer Survival between Public and Private Care in New Zealand: Which Factors Contribute? PLoS One. 2016 Apr 7;11(4):e0153206. doi: 10.1371/journal.pone.0153206.
20. Huerta L, Manrique A, Szafranska J, et al. Brain metastases in colorectal cancer: prognostic factors and survival analysis. Int J Colorectal Dis. 2018;33(11):1517-23.
21. Merrie A, Phillips L, Yun K, et al. Skip metastases in colon cancer: assessment by lymph node mapping using molecular detection. Surgery. 2001 Jun;129(6):684-91. doi: 10.1067/msy.2001.113887.
22. Read TE, Mutch MG, Chang BW, et al. Locoregional recurrence and survival after curative resection of adenocarcinoma of the colon. J Am Coll Surg. 2002 Jul;195(1):33-40. doi: 10.1016/s1072-7515(02)01224-3.
23. Warwick R and Page R. Resection of pulmonary metastases from colorectal carcinoma. Eur J Surg Oncol. 2007 Dec;33 Suppl 2:S59-63. doi: 10.1016/j.ejso.2007.09.018.
24. Chahine G, Ibrahim T, Felefly T, et al. Colorectal cancer and brain metastases: An aggressive disease with a different response to treatment. Tumori. 2019;105(5):427-33.
25. Meguid R, Slidell M, Wolfgang C, et al. Is there a difference in survival between right- versus left-sided colon cancers? Ann Surg Oncol. 2008 Sep;15(9):2388-94. doi: 10.1245/s10434-008-0015-y.
26. Asghari-Jafarabadi M, Wilkins S, Plazzer JP, et al. Prognostic factors and survival disparities in right-sided versus left-sided colon cancer. Sci Rep. 2024 May 29;14(1):12306. doi: 10.1038/s41598-024-63143-3.
27. Bourakkadi Idrissi M, El Bouhaddouti H, Mouaqit O, et al. Left-Sided Colon Cancer and Right-Sided Colon Cancer: Are They the Same Cancer or Two Different Entities? Cureus. 2023 Apr 14;15(4):e37563. doi: 10.7759/cureus.37563.
28. Mangone L, Pinto C, Mancuso P, et al. Colon cancer survival differs from right side to left side and lymph node harvest number matter. BMC Public Health. 2021 May 12;21(1):906. doi: 10.1186/s12889-021-10746-4.
29. Janssens K, Fransen E, Van Camp G, et al. A Belgian Population-Based Study Reveals Subgroups of Right-sided Colorectal Cancer with a Better Prognosis Compared to Left-sided Cancer. Oncologist. 2023 Jun 2;28(6):e331-e340. doi: 10.1093/oncolo/oyad074.
30. Tie J, Lipton L, Desai J, et al. KRAS Mutation Is Associated with Lung Metastasis in Patients with Curatively Resected Colorectal Cancer. Clin Cancer Res. 2011;17(5):1122-30.
31. Müller S, Köhler F, Hendricks A, et al. Brain Metastases from Colorectal Cancer: A Systematic Review of the Literature and Meta-Analysis to Establish a Guideline for Daily Treatment. Cancers (Basel). 2021 Feb 21;13(4):900. doi: 10.3390/cancers13040900.
32. Imaizumi J, Shida D, Narita Y, et al. Prognostic factors of brain metastases from colorectal cancer. BMC Cancer. 2019;19(1):755.
33. Mege D, Sans A, Ouaissi M, et al. Brain metastases from colorectal cancer: characteristics and management. ANZ J Surg. 2018;88(3):140-5.
34. Damiens K, Ayoub J, Lemieux B, et al. Clinical features and course of brain metastases in colorectal cancer: an experience from a single institution. Curr Oncol. 2012;19(5):254-8.